Sol-Gel Technologies Ltd.
SLGL$2.51B
Mid CapNASDAQPharmaceutical Preparations🇺🇸North AmericaNESS ZIONA34 employees
Drugs in Pipeline
8
Phase 3 Programs
7
Upcoming Catalysts
1
Next Catalyst
Aug 15, 2026
22wMarket Overview
Stock performance and key metrics
SLGL News
Catalyst Timeline
1 upcoming, 0 past
Drug Pipeline
S6G5T-8
Acne Vulgaris
S6G5T-3
Acne Vulgaris
Patidegib Topical Gel, 2%
Basal Cell Nevus Syndrome
S5G4T-2
Papulopustular Rosacea
S5G4T-1
Papulopustular Rosacea
5-FU Cream
Actinic Keratosis (AK)
Patidegib Topical Gel
Gorlin Syndrome
DER 45 EV
Rosacea
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
S6G5T-8 | Phase 3 | Acne Vulgaris | - | - |
S6G5T-3 | Phase 3 | Acne Vulgaris | - | - |
Patidegib Topical Gel, 2% | Phase 3 | Basal Cell Nevus Syndrome | - | - |
S5G4T-2 | Phase 3 | Papulopustular Rosacea | - | - |
S5G4T-1 | Phase 3 | Papulopustular Rosacea | - | - |
5-FU Cream | Phase 3 | Actinic Keratosis (AK) | - | - |
Patidegib Topical Gel | Phase 3 | Gorlin Syndrome | - | - |
DER 45 EV | Phase 2 | Rosacea | - | - |
Regulatory Approvals
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply